Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

http://www.wikidata.org/entity/Q33373436

about

Chemotherapy versus best supportive care for extensive small cell lung cancer Targeted drugs in small-cell lung cancer Treatment for small cell lung cancer, where are we now?-a review Targeting angiogenesis in small cell lung cancer Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients New and emerging developments in extensive-stage small cell lung cancer therapeutics Checkpoint inhibitors in lung cancer: latest developments and clinical potential The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Lung cancer: current diagnosis and treatment Treatment options for small cell lung cancer - do we have more choice?Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature.Neuroendocrine carcinoma of the cervix presenting as intractable hyponatremic seizures due to paraneoplastic SIADH-a rare case report and brief review of the literature Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Small cell lung cancer: therapies and targets A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer The role of anthracyclines in small cell lung cancer.Topotecan in the treatment of relapsed small cell lung cancer.Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer Current and emerging pharmacotherapies for the treatment of relapsed small cell lung cancer.Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.

P2860

Q24240652-F341466E-6498-4EC3-850B-35C7BD6E5169 Q26767017-5882B125-B897-483C-B43D-9A8FA596954C Q26767023-20A2E165-7762-4A93-97AC-132DC491A7CD Q28068385-EFD59D7C-C5FB-463F-9B89-7E0D4A7BAF24 Q28072672-21CA1E4B-19C9-45FA-B5A3-5BE9060A4610 Q28076304-3DE3600D-6C8D-405F-B0CB-AFD9E03D2971 Q28076467-D6F20CE4-8D9C-4AFD-8474-C57CD24D9C3E Q28395836-7C730792-DDB9-4423-8E2E-D047E5FC8C5C Q28596809-D40A54F0-3F79-46A2-B761-27BB7B9AFFEE Q33383208-BA556E35-5F66-45CB-BBDB-04C3A7DA8E5B Q33391448-3CCC97BD-6B95-451F-903A-C661EC4EFB9F Q33395544-5FA07DFC-9CB2-409E-B1AD-64467A3F6368 Q33400292-955FBA98-C00C-4BF3-A8C0-158A88485F67 Q33403230-B4855528-C71E-4CFA-9294-AF6509240709 Q33407183-F23ED337-EE13-4A29-8007-BD1849C3B205 Q33417320-5F19D5D0-3CEB-44C3-A864-83EE6A540070 Q33417537-2FC16720-084B-4276-BA2B-4FB3AE612FAC Q33423381-196E1C1D-E928-4E7A-8298-A83290669E05 Q33424869-D0041033-D13F-4D4A-8886-588E048661A4 Q33434764-BBC7E100-AA6F-49B2-9B28-B08B1FDBEFB8 Q33437893-72DF796E-2AB9-41F2-95AE-029114A80167 Q33443519-D5745CE6-ED13-4FDF-A8F6-17DF77F38B00 Q33554085-6D1132C0-E3E6-4016-BE76-33183E65BB30 Q33723735-AD55A46D-638E-4C6E-B5DA-9AED486F4887 Q33780751-13FB37A0-B397-4586-A611-BEC42ED2D65B Q33799729-488E97B0-36F1-4079-A2C2-6C31FBE43D6E Q33988305-8EB6680A-6E27-4DBC-A372-086021787DB5 Q34000985-40239B29-C6DC-4518-A5A9-CACAB3218D90 Q34026037-1569B93B-0799-44F7-90AB-4ABBC51B66CE Q34250859-EC27BE80-3BB6-4F72-B32D-6D7CF17AF72E Q34313435-828AF7D8-81A8-4A5B-ABBC-68B4E054FE5E Q34358063-6BD12471-8D52-4D2F-AA56-C8EBAE572E6F Q34363428-593C4630-276B-49EE-8185-E8F8BD79A337 Q34512144-67E89AA8-D473-4603-942A-31057D87A808 Q34565988-8624B3BC-21E6-45BB-B268-453836A94F1C Q34653756-F0FBE18D-8261-43CA-A62A-1FEA5D82D916 Q34866341-26E2D652-B0A7-4E15-B8DF-7B3B6716B653 Q35155464-130FB311-5297-456B-A6EE-F0115D85B16E Q35587164-03096039-64E6-48F9-9B0A-BC5F28B6ABED Q35713556-EB79B599-7BF3-41D5-A2C0-D947DDF5FAD0

P2860

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

http://www.wikidata.org/entity/Q33373436

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@ast

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@en

type

label

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@ast

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@en

prefLabel

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@ast

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@en

P1433

Q33373436-2F16E4AE-03B2-4983-81E5-2F363494AB51

P1476

Q33373436-DA079D5C-B058-4BC6-8326-70C7198E88AD

P2093

Q33373436-02BD43A3-7206-40D5-92FC-89CCBAD007B5

Q33373436-23440C8F-6DC5-479C-9BD1-7699ECB4B88D

Q33373436-2B8C5EE2-C41C-43A3-8D55-13D051E55FA7

Q33373436-5B8DC03A-C8E0-4EBE-BA45-EDA226E3E00F

Q33373436-5DFC6523-9D2A-4620-87A9-E852ABE83E54

Q33373436-791B8CD3-D209-40E0-853C-5A09C5864C46

Q33373436-826F5B0E-BEA1-4BD3-B030-A7D2A64C768B

Q33373436-A9DCBD0D-7FD3-4220-AF55-F677736B4854

Q33373436-C0952CA2-9EA0-444A-BBA9-A0FE2AC1D38F

Q33373436-D4CF00CC-FC1E-4BD3-BE1E-85076761D751

P304

Q33373436-79EF922E-608E-4A39-AC30-96562A33582A

P31

Q33373436-57E7EC1E-AC96-4B01-B777-2880655BE66A

P356

Q33373436-ED10BA8A-38F9-41B9-9AB7-C0FA8395D181

P407

Q33373436-B25B6F79-6E34-4632-8ADD-E7B9D2B629F4

P433

Q33373436-30042249-BCD0-4C2E-B920-B9AEB265DAE6

P478

Q33373436-5349297F-AAC9-4F4E-97B2-875989F9BE02

P577

Q33373436-C32686EF-4DC9-4788-B2CB-C2CB1A65CA80

P5875

Q33373436-4C35B94E-25F3-4586-93E7-8116BA5706E7

P698

Q33373436-92747440-4AB9-4B81-9D36-1C7E4FEC8626

P921

Q33373436-7484BD82-E4FC-40DA-B8C7-DB9717AC1D04

P356

JCO.2006.06.5821

P1433

Journal of Clinical Oncology

P1476

Phase III trial comparing supp ...... lapsed small-cell lung cancer.

@en

P2093

Branka Cuceviá

http://www.w3.org/2001/XMLSchema#string

Gabor Juhasz

http://www.w3.org/2001/XMLSchema#string

Graham A Ross

http://www.w3.org/2001/XMLSchema#string

Graham C Dane

http://www.w3.org/2001/XMLSchema#string

Hristo Tsekov

http://www.w3.org/2001/XMLSchema#string

Mary E R O'Brien

http://www.w3.org/2001/XMLSchema#string

Nicholas Thatcher

http://www.w3.org/2001/XMLSchema#string

Theresa Crofts

http://www.w3.org/2001/XMLSchema#string

Tudor-Eliade Ciuleanu

http://www.w3.org/2001/XMLSchema#string

Yaroslav Shparyk

http://www.w3.org/2001/XMLSchema#string

P304

5441-5447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.06.5821

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6662489

http://www.w3.org/2001/XMLSchema#string

P698

17135646

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial